Expert recommendations for the management of diabetic macular edema with intravitreal dexamethasone implant: A Turkish Delphi study


Batioglu F., YANIK ODABAŞ Ö., SAATCİ A. O., Eldem B., AKKIN C., AFRASHİ F., ...More

EUROPEAN JOURNAL OF OPHTHALMOLOGY, vol.33, no.1, pp.398-407, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.1177/11206721221117695
  • Journal Name: EUROPEAN JOURNAL OF OPHTHALMOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.398-407
  • Keywords: Delphi consensus, dexamethasone implant, diabetic macular edema, GROWTH-FACTOR THERAPY, RANIBIZUMAB, AFLIBERCEPT, LASER, TRIAMCINOLONE, RETINOPATHY, PREVALENCE, CONVERSION, TRIAL
  • Hacettepe University Affiliated: Yes

Abstract

Purpose To provide consensus on the clinical use of intravitreal dexamethasone (DEX) implant for the treatment of diabetic macular edema (DME) in Turkey. Methods A panel of 22 retina experts prepared 77 statements of recommendation, and 80 retinal specialists practicing in Turkey were chosen to vote either in support or against each one. A Delphi-based method was used through which the ophthalmologists were able to view all of the results anonymously after two rounds and modify their subsequent answers. The survey was conducted via a mini website, and statements without consensus were resent to the specialists with the latest vote results a week later. Results A total of 72 ophthalmologists answered the first and second round questions. After the first stage, consensus was achieved on 55 of the statements, leaving 22 without agreement. After the second stage, consensus was reached on 11 of the remaining statements. Strong consensus was achieved on statements regarding the etiopathogenesis of DME and the first-line indications and safety of the DEX implant procedure. The panel recommended the use of DEX implant for patients with an arterial thromboembolic event in the last three months and also agreed that pro re nata DEX implant treatment not only provides better outcomes for DME patients but also reduces the treatment burden for those who could not receive an adequate number of anti-vascular endothelial growth factor (VEGF) injections. Conclusion This study provides clinical consensus and recommendations about the use of DEX implant in the clinical practice of DME management in Turkey.